(Q38349665)

30 June 2019

review article

1 reference

title

Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches (English)

1 reference

30 June 2019

main subject

hepatocellular carcinoma

1 reference

Tim F Greten

1

1 reference

30 June 2019

Xin W Wang

series ordinal

2

1 reference

30 June 2019

Firouzeh Korangy

series ordinal

3

1 reference

30 June 2019

language of work or name

English

0 references

publication date

9 February 2015

1 reference

30 June 2019

published in

Gut

1 reference

30 June 2019

volume

64

1 reference

30 June 2019

issue

5

1 reference

30 June 2019

page(s)

842-848

1 reference

30 June 2019

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Immunity, Inflammation, and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Immune responses in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Hepatocellular carcinoma epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Reversing hepatocellular carcinoma progression by using networked biological therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Increased risk of hepatobiliary cancers after hospitalization for autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Abscopal effect of radiation on lung metastases of hepatocellular carcinoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Abscopal effect on hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Spontaneous regression of a large hepatocellular carcinoma with skull metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Thermal ablation of tumours: biological mechanisms and advances in therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Hepatocellular carcinoma from an immunologic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Hepatic immune regulation and its involvement in viral hepatitis infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Immune tolerance: what is unique about the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

History of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Immunological off-target effects of standard treatments in gastrointestinal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Role of Stat3 in suppressing anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

STATs in cancer inflammation and immunity: a leading role for STAT3

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

NK cells are the crucial antitumor mediators when STAT3-mediated immunosuppression is blocked in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Human CCR4+ CCR6+ Th17 cells suppress autologous CD8+ T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Elevated pretherapy serum IL17 in primary hepatocellular carcinoma patients correlate to increased risk of early recurrence after curative hepatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

IL-17A produced by γδ T cells promotes tumor growth in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

MicroRNA expression, survival, and response to interferon in liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Development of a miR-26 companion diagnostic test for adjuvant interferon-alpha therapy in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Hepatic RIG-I predicts survival and interferon-α therapeutic response in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Immune parameters affecting the efficacy of chemotherapeutic regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Attenuated liver tumor formation in the absence of CCR2 with a concomitant reduction in the accumulation of hepatic stellate cells, macrophages and neovascularization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Regression of established liver tumor induced by monoepitopic peptide-based immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Snapshot: genetic mouse models of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Animal models of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Microsphere priming facilitates induction of potent therapeutic T-cell immune responses against autochthonous liver cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Hyper-IL-15 suppresses metastatic and autochthonous liver cancer by promoting tumour-specific CD8+ T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

21 January 2018

Cancer genome landscapes

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Mutational heterogeneity in cancer and the search for new cancer-associated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

CD40 AND CD154 IN CELL-MEDIATED IMMUNITY

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Agonistic CD40 antibodies and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Adenovirus-mediated CD40L gene therapy induced both humoral and cellular immunity against rat model of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Oncolytic viruses as anticancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

A hypoxia- and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

21 January 2018

Immunotherapy of HCC.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Potential of immunotherapy for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Harnessing the immune system for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Antitumour immunity gets a boost

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307990

Combination of systemic thioacetamide (TAA) injections and ethanol feeding accelerates hepatic fibrosis in C3H/He mice and is associated with intrahepatic up regulation of MMP-2, VEGF and ICAM-1

21 January 2018

1 reference

12 December 2020

Immunotherapy of hepatocellular carcinoma

1 reference

12 December 2020

Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety

1 reference

12 December 2020

Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients

1 reference

12 December 2020

Regression of hepatocellular carcinoma

1 reference

12 December 2020

Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: a comparative study.

1 reference

12 December 2020

Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC

1 reference

12 December 2020

Radiofrequency ablation for the treatment of HCC--maybe much more than simple tumor destruction?

1 reference

12 December 2020

AFP-specific immunotherapy impairs growth of autochthonous hepatocellular carcinoma in mice

1 reference

12 December 2020

Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization

1 reference

12 December 2020

Decrease in size of non-treated lesions after cryoablation for hepatocellular carcinoma

1 reference

12 December 2020

[Studies on cases of spontaneous regression of cancer in Japan in 2011, and of hepatic carcinoma, lung cancer and pulmonary metastases in the world between 2006 and 2011].

1 reference

12 December 2020

Advances in clinical application of cryoablation therapy for hepatocellular carcinoma and metastatic liver tumor

1 reference

12 December 2020

Hepatocellular Carcinoma Regression After Cessation of Immunosuppressive Therapy

1 reference

12 December 2020

Endotoxin and bacteria in portal blood

1 reference

12 December 2020

10.1136/GUTJNL-2014-307990

Identifiers

DOI

1 reference

30 June 2019

PMC publication ID

6311419

1 reference

30 June 2019

PubMed publication ID

25666193

1 reference

30 June 2019